Galmed Pharmaceuticals (NASDAQ:GLMD) Earns “Hold” Rating from Maxim Group

Maxim Group restated their hold rating on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note published on Friday,Benzinga reports.

Separately, StockNews.com assumed coverage on Galmed Pharmaceuticals in a research note on Friday, March 28th. They set a “sell” rating for the company.

Galmed Pharmaceuticals Price Performance

Galmed Pharmaceuticals stock opened at $1.34 on Friday. Galmed Pharmaceuticals has a fifty-two week low of $1.28 and a fifty-two week high of $23.80. The firm has a fifty day moving average price of $2.22 and a two-hundred day moving average price of $3.28. The firm has a market cap of $862,960.00, a price-to-earnings ratio of -0.08 and a beta of 0.70.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.